Table 4.
Treatments of Patients Infected With SARS-CoV-2
| Overall(n=239) (n, %) | General group (n=176) (n, %) | Severe and critical group (n=63) (n, %) | p Value | |
|---|---|---|---|---|
| Antiviral therapy | ||||
| Oseltamivir | 239(100) | 176(100) | 63(100) | |
| Lopinavir | 44 (18.4) | 12 (6.8) | 32 (50.7) | < 0.001 |
| No antiviral drug | 0 | 0 | 0 | |
| Other treatments | ||||
| Hydroxychloroquine | 188 (78.6) | 143 (81.25) | 45 (71.4) | 0.238 |
| Antibiotic* | 148(62) | 105 (59.6) | 33 (52.4) | 0.346 |
| Glucocorticoid | 78 (32.9) | 34 (19.4) | 44 (69.8) | < 0.001 |
| Supportive therapy | ||||
| Intranasal oxygen inhalation | 121 (50.6) | 61 (34.5) | 60 (95.8) | < 0.001 |
| High flow oxygen | 13 (5.4) | 0 | 13 (20.6) | < 0.001 |
| Non-invasive and invasive mechanical ventilation | 8 (3.3) | 0 | 8 (12.7) | < 0.001 |
* including Azithromycin or Levofloxacin